Compare Johnson & Johnson (JNJ) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares Ultra QQQ ETF — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while ProShares Ultra QQQ ETF trades at $92.1. The key difference: Johnson & Johnson pays a 2.06% dividend while ProShares Ultra QQQ ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | QLD | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $100.53 |
52-Week Low | $172.78 | $57.16 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
QLD trades at $92.70, up 1.16% with a bullish technical outlook supported by moving averages. The leveraged ETF shows strong momentum with RSI indicating potential overbought conditions near-term. Recent institutional buying by 180 Wealth Advisors and positive media coverage highlight tactical interest in tech-focused leveraged strategies.
As a 2x leveraged Nasdaq-100 ETF, QLD offers amplified exposure to large-cap tech but carries significant volatility risks. The fund has delivered substantial long-term returns but experienced deep drawdowns during market stress. Investors should carefully consider risk tolerance given the daily rebalancing mechanics and concentration in technology sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
